In a rush to bring Xarelto to market, drugmakers Bayer and Janssen Pharmaceuticals skipped needed testing that would have provided the basis for a more accurate warning label, plaintiffs counsel in the latest trial over the blood thinner told a Philadelphia jury Wednesday.

Pensacola, Florida, attorney Neil Overholtz of Aylstock, Witkin, Kreis & Overholtz told jurors during closing arguments in Cooney v. Janssen that, after learning about the efficacy and risks of a 20 milligram dose of the blood thinner, the defendants should have worked to develop a 10 milligram dose—a dose that Overholtz told jurors likely would not have caused the severe bleed that his client, Kevin Cooney, suffered while taking Xarelto.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]